• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖原贮积病 I 型中肝细胞腺瘤形成的自然史。

Natural history of hepatocellular adenoma formation in glycogen storage disease type I.

机构信息

Glycogen Storage Disease Program and Division of Pediatric Endocrinology, Department of Pediatrics, University of Florida, Gainesville, FL 32610-0296, USA.

出版信息

J Pediatr. 2011 Sep;159(3):442-6. doi: 10.1016/j.jpeds.2011.02.031. Epub 2011 Apr 9.

DOI:10.1016/j.jpeds.2011.02.031
PMID:21481415
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3135733/
Abstract

OBJECTIVE

To characterize the natural history and factors related to hepatocellular adenoma (HCA) development in glycogen storage disease type Ia (GSD Ia).

STUDY DESIGN

Retrospective chart review was performed for 117 patients with GSD Ia. Kaplan-Meier analysis of HCA progression among two groups of patients with GSD Ia (5-year mean triglyceride concentration ≤ 500 mg/dL and >500 mg/dL); analysis of serum triglyceride concentration, body mass index SDS, and height SDS between cases at time of HCA diagnosis and age- and sex-matched control subjects.

RESULTS

Logrank analysis of Kaplan-Meier survival curve demonstrated a significant difference in progression to HCA between the 5-year mean triglyceride groups (P = .008). No significant difference was detected in progression to adenoma event between sexes. Serum triglyceride concentration was significantly different at time of diagnosis of adenoma (737 ± 422 mg/dL) compared with control subjects (335 ± 195 mg/dL) (P = .009). Differences in height SDS (P = .051) and body mass index SDS (P = .066) approached significance in our case-control analysis.

CONCLUSION

Metabolic control may be related to HCA formation in patients with GSD Ia. Optimizing metabolic control remains critical, and further studies are warranted to understand the pathogenesis of adenoma development.

摘要

目的

描述糖原贮积病 Ia 型(GSD Ia)中肝细胞腺瘤(HCA)的自然史和相关因素。

研究设计

对 117 例 GSD Ia 患者进行回顾性图表审查。对 GSD Ia 两组患者(5 年平均甘油三酯浓度≤500mg/dL 和>500mg/dL)中 HCA 进展的 Kaplan-Meier 分析;在 HCA 诊断时和年龄、性别匹配的对照组中,分析病例的血清甘油三酯浓度、体重指数 SDS 和身高 SDS。

结果

Kaplan-Meier 生存曲线的对数秩分析显示,两组 5 年平均甘油三酯的 HCA 进展差异有统计学意义(P =.008)。性别之间腺瘤事件的进展无显著差异。与对照组相比,诊断为腺瘤时的血清甘油三酯浓度明显升高(737±422mg/dL 比 335±195mg/dL)(P =.009)。我们的病例对照分析中,身高 SDS(P =.051)和体重指数 SDS(P =.066)的差异有统计学意义。

结论

代谢控制可能与 GSD Ia 患者的 HCA 形成有关。优化代谢控制仍然至关重要,需要进一步研究以了解腺瘤发展的发病机制。

相似文献

1
Natural history of hepatocellular adenoma formation in glycogen storage disease type I.糖原贮积病 I 型中肝细胞腺瘤形成的自然史。
J Pediatr. 2011 Sep;159(3):442-6. doi: 10.1016/j.jpeds.2011.02.031. Epub 2011 Apr 9.
2
Hepatocellular adenoma and metabolic balance in patients with type Ia glycogen storage disease.Ia型糖原贮积病患者的肝细胞腺瘤与代谢平衡
Mol Genet Metab. 2008 Apr;93(4):398-402. doi: 10.1016/j.ymgme.2007.10.134. Epub 2008 Feb 20.
3
Identification of differentially expressed microRNAs in human hepatocellular adenoma associated with type I glycogen storage disease: a potential utility as biomarkers.鉴定与 I 型糖原贮积病相关的人肝细胞腺瘤中差异表达的 microRNAs:作为生物标志物的潜在用途。
J Gastroenterol. 2014 Aug;49(8):1274-84. doi: 10.1007/s00535-013-0890-2. Epub 2013 Oct 16.
4
Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia.Ia型糖原贮积病患者肝细胞腺瘤的切除术
J Hepatol. 2007 Nov;47(5):658-63. doi: 10.1016/j.jhep.2007.05.012. Epub 2007 Jun 18.
5
Reappraisal of the Role of Portacaval Shunting in the Growth of Patients With Glycogen Storage Disease Type I in the Era of Liver Transplantation.肝移植时代门腔分流术在Ⅰ型糖原贮积病患者生长发育中作用的重新评估
Transplantation. 2016 Mar;100(3):585-92. doi: 10.1097/TP.0000000000000884.
6
Chromosomal and genetic alterations in human hepatocellular adenomas associated with type Ia glycogen storage disease.与 Ia 型糖原贮积病相关的人肝细胞腺瘤中的染色体和基因改变。
Hum Mol Genet. 2009 Dec 15;18(24):4781-90. doi: 10.1093/hmg/ddp441. Epub 2009 Sep 16.
7
Normoglycemia alone is insufficient to prevent long-term complications of hepatocellular adenoma in glycogen storage disease type Ib mice.单纯血糖正常不足以预防糖原贮积病 Ib 型小鼠肝细胞腺瘤的长期并发症。
J Hepatol. 2009 Nov;51(5):909-17. doi: 10.1016/j.jhep.2008.11.026. Epub 2009 Feb 5.
8
Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.糖原贮积病Ⅰ型患者肝细胞腺瘤的分子特征。
J Hepatol. 2013 Feb;58(2):350-7. doi: 10.1016/j.jhep.2012.09.030. Epub 2012 Oct 6.
9
Successful treatment of multiple hepatocellular adenomas with percutaneous radiofrequency ablation.经皮射频消融治疗多发性肝细胞腺瘤。
World J Gastroenterol. 2013 Nov 14;19(42):7480-6. doi: 10.3748/wjg.v19.i42.7480.
10
Activation of tumor-promoting pathways implicated in hepatocellular adenoma/carcinoma, a long-term complication of glycogen storage disease type Ia.肿瘤促进途径的激活与肝腺瘤/肝癌有关,这是糖原贮积病 I 型的一种长期并发症。
Biochem Biophys Res Commun. 2020 Jan 29;522(1):1-7. doi: 10.1016/j.bbrc.2019.11.061. Epub 2019 Nov 15.

引用本文的文献

1
Clinical characteristics of 50 hepatocellular adenoma patients among 164 cases of glycogen storage disease type Ia.164例Ia型糖原贮积病患者中50例肝细胞腺瘤患者的临床特征
Eur J Pediatr. 2025 Jun 30;184(7):458. doi: 10.1007/s00431-025-06180-y.
2
Empagliflozin as treatment in glycogen storage disease type IB patients.恩格列净用于治疗1B型糖原贮积病患者。
Mol Genet Metab Rep. 2025 May 3;43:101226. doi: 10.1016/j.ymgmr.2025.101226. eCollection 2025 Jun.
3
Diagnosing glycogen storage disease type 1b in adulthood: A case with multiple hepatocellular adenomas.

本文引用的文献

1
Metabolism and proliferation share common regulatory pathways in cancer cells.在癌细胞中,代谢和增殖共享共同的调控途径。
Oncogene. 2010 Aug 5;29(31):4369-77. doi: 10.1038/onc.2010.182. Epub 2010 May 31.
2
Subtype classification of hepatocellular adenoma.肝细胞腺瘤的亚型分类。
Dig Surg. 2010;27(1):39-45. doi: 10.1159/000268406. Epub 2010 Apr 1.
3
Chromosomal and genetic alterations in human hepatocellular adenomas associated with type Ia glycogen storage disease.与 Ia 型糖原贮积病相关的人肝细胞腺瘤中的染色体和基因改变。
成人期1b型糖原贮积病的诊断:一例合并多发性肝细胞腺瘤的病例
Hepatol Forum. 2024 Dec 25;6(1):26-28. doi: 10.14744/hf.2024.2024.0008. eCollection 2025.
4
Efficacy of magnetic resonance imaging in managing glycogen storage disease.磁共振成像在糖原贮积病管理中的疗效
Orphanet J Rare Dis. 2025 Mar 27;20(1):144. doi: 10.1186/s13023-025-03605-7.
5
MRI features of hepatocellular adenomas in children: clinical and radiological review.儿童肝细胞腺瘤的MRI特征:临床与影像学综述
Pediatr Radiol. 2025 Mar;55(3):488-498. doi: 10.1007/s00247-025-06177-7. Epub 2025 Jan 31.
6
Short and long-term acceptability and efficacy of extended-release cornstarch in the hepatic glycogen storage diseases: results from the Glyde study.延长释放型玉米淀粉在肝糖原贮积病中的短期和长期可接受性和疗效:Glyde 研究结果。
Orphanet J Rare Dis. 2024 Jul 9;19(1):258. doi: 10.1186/s13023-024-03274-y.
7
Clinical spectrum, over 12-year follow-up and experience of SGLT2 inhibitors treatment on patients with glycogen storage disease type Ib: a single-center retrospective study.糖原贮积病 Ib 型患者的临床谱、超过 12 年的随访及 SGLT2 抑制剂治疗经验:一项单中心回顾性研究。
Orphanet J Rare Dis. 2024 Apr 11;19(1):155. doi: 10.1186/s13023-024-03137-6.
8
Integrative analysis of pathogenic variants in glucose-6-phosphatase based on an AlphaFold2 model.基于AlphaFold2模型的葡萄糖-6-磷酸酶致病变异体的综合分析
PNAS Nexus. 2024 Jan 29;3(2):pgae036. doi: 10.1093/pnasnexus/pgae036. eCollection 2024 Feb.
9
Development of hepatocellular adenomas in a patient with glycogen storage disease Ia treated with growth hormone therapy.一名接受生长激素治疗的糖原贮积病Ia型患者发生肝细胞腺瘤。
JIMD Rep. 2023 Aug 18;64(5):303-311. doi: 10.1002/jmd2.12381. eCollection 2023 Sep.
10
Glycogen storage diseases: An update.糖原贮积病:更新。
World J Gastroenterol. 2023 Jul 7;29(25):3932-3963. doi: 10.3748/wjg.v29.i25.3932.
Hum Mol Genet. 2009 Dec 15;18(24):4781-90. doi: 10.1093/hmg/ddp441. Epub 2009 Sep 16.
4
Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience.肝细胞腺瘤的管理与表型分类:波尔多经验
Hepatology. 2009 Aug;50(2):481-9. doi: 10.1002/hep.22995.
5
Hyperlipidemia in glycogen storage disease type III: effect of age and metabolic control.III型糖原贮积病中的高脂血症:年龄及代谢控制的影响
J Inherit Metab Dis. 2008 Dec;31(6):729-32. doi: 10.1007/s10545-008-0919-5. Epub 2008 Aug 19.
6
Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease.导致Ia型糖原贮积病的葡萄糖-6-磷酸酶-α(G6PC)基因突变。
Hum Mutat. 2008 Jul;29(7):921-30. doi: 10.1002/humu.20772.
7
Hepatocellular adenoma and metabolic balance in patients with type Ia glycogen storage disease.Ia型糖原贮积病患者的肝细胞腺瘤与代谢平衡
Mol Genet Metab. 2008 Apr;93(4):398-402. doi: 10.1016/j.ymgme.2007.10.134. Epub 2008 Feb 20.
8
Fatty acid synthase and cancer: new application of an old pathway.脂肪酸合酶与癌症:旧有通路的新应用
Cancer Res. 2006 Jun 15;66(12):5977-80. doi: 10.1158/0008-5472.CAN-05-4673.
9
Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC.肝细胞腺瘤的基因型-表型相关性:新分类及与肝癌的关系
Hepatology. 2006 Mar;43(3):515-24. doi: 10.1002/hep.21068.
10
Overexpression of fatty acid synthase in chemically and hormonally induced hepatocarcinogenesis of the rat.脂肪酸合酶在大鼠化学诱导和激素诱导肝癌发生过程中的过表达
Lab Invest. 2005 Jan;85(1):99-108. doi: 10.1038/labinvest.3700206.